Gut microbiota from patients with arteriosclerotic CSVD induces higher IL-17A production in neutrophils via activating RORγt

• Published in: Science advances Vol. 7; no. 4
• Main Authors: Cai, Wei, Chen, Xiaodong, Men, Xuejiao, Ruan, Hengfang, Hu, Mengyan, Liu, Sanxin, Lu, Tingting, Liao, Jinchi, Zhang, Bingjun, Lu, Danli, Huang, Yinong, Fan, Ping, Rao, Junping, Lei, Chunyan, Wang, Jihui, Ma, Xiaomeng, Zhu, Qiang, Li, Lili, Zhu, Xiuyun, Hou, Yujiao, Li, Shu, Dong, Qing, Tian, Qing, Ai, Lulu, Luo, Wenjing, Zuo, Mengyun, Shen, Liping, Xie, Congyan, Song, Hongzhong, Xu, Ganlin, Zheng, Kangdi, Zhang, Zhao, Lu, Yongjun, Qiu, Wei, Chen, Tao, Xiang, Andy Peng, Lu, Zhengqi
• Format: Journal Article
• Language: English
• Published: United States American Association for the Advancement of Science 22.01.2021
• Subjects: Aged; Animals; Diseases and Disorders; Gastrointestinal Microbiome - physiology; Humans; Interleukin-17; Mice; Microbiology; Neutrophils; Nuclear Receptor Subfamily 1, Group F, Member 3; Plant Extracts; SciAdv r-articles
• ISSN: 2375-2548; 2375-2548
• DOI: 10.1126/sciadv.abe4827

The intestinal microbiota shape the host immune system and influence the outcomes of various neurological disorders. Arteriosclerotic cerebral small vessel disease (aCSVD) is highly prevalent among the elderly with its pathological mechanisms yet is incompletely understood. The current study investigated the ecology of gut microbiota in patients with aCSVD, particularly its impact on the host immune system. We reported that the altered composition of gut microbiota was associated with undesirable disease outcomes and exacerbated inflammaging status. When exposed to the fecal bacterial extracts from a patient with aCSVD, human and mouse neutrophils were activated, and capacity of interleukin-17A (IL-17A) production was increased. Mechanistically, RORγt signaling in neutrophils was activated by aCSVD-associated gut bacterial extracts to up-regulate IL-17A production. Our findings revealed a previously unrecognized implication of the gut-immune-brain axis in aCSVD pathophysiology, with therapeutic implications.